| Meta-analysis of darunavir studies | ||
| Meta-analysis of darunavir studies | ||
Jun 9 2021 |
et al., Frontiers in Medicine, doi:10.3389/fmed.2021.639970 | Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study |
| 89% higher mortality (p<0.0001). Retrospective 3,451 hospitalized COVID-19 patients in Italy showing higher mortality with darunavir/cobicistat. | ||
Apr 1 2021 |
et al., AIDS Research and Human Retroviruses, doi:10.1089/AID.2020.0305 | Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia |
| 150% higher mortality (p=0.0001) and 48% higher combined mortality/intubation (p=0.03). Retrospective 273 hospitalized COVID-19 patients showing higher mortality with darunavir/cobicistat treatment. | ||
Dec 31 2020 |
et al., Yonsei Medical Journal, doi:10.3349/ymj.2020.61.9.826 | Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection |
| 87% lower mortality (p=0.009). Retrospective 110 critically ill COVID-19 patients in South Korea showing lower mortality with darunavir/cobicistat treatment. | ||
Jul 29 2020 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa321 | Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19” |
| 32% higher mortality (p=0.21). Retrospective 328 hospitalized COVID-19 patients in Italy showing no mortality benefit with darunavir/ritonavir treatment. | ||
Jun 21 2020 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa241 | Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19 |
| 22% worse viral clearance (p=0.64). RCT 30 mild COVID-19 patients showing no benefit of darunavir/cobicistat compared to standard care for viral clearance. | ||
